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Abstract: Natural product antimicrobial peptides (AMPs) have been proposed as 
promising agents against the Leishmania species, insect vector borne protozoan parasites 
causing the neglected tropical disease leishmaniasis. However, recent studies have shown 
that the mammalian pathogenic amastigote form of L. mexicana, a causative agent of 
cutaneous leishmaniasis, is resistant to the amphibian-derived temporin family of AMPs 
when compared to the insect stage promastigote form. The mode of resistance is unknown, 
however the insect and mammalian stages of Leishmania possess radically different cell 
surface coats, with amastigotes displaying low (or zero) quantities of lipophosphoglycan 
(LPG) and proteophosphoglycan (PPG), macromolecules which form thick a glycocalyx in 
promastigotes. It has been predicted that negatively charged LPG and PPG influence the 
sensitivity/resistance of promastigote forms to cationic temporins. Using LPG and PPG 
mutant L. mexicana, and an extended range of temporins, in this study we demonstrated 
that whilst LPG has little role, PPG is a major factor in promastigote sensitivity to the 
temporin family of AMPs, possibly due to the conferred anionic charge. Therefore, the 
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lack of PPG seen on the surface of pathogenic amastigote L. mexicana may be implicated 
in their resistance to these peptides. 
Keywords: Leishmania mexicana; cutaneous leishmaniasis; drug therapy;  
antimicrobial peptide 
 
1. Introduction 
Leishmaniasis is a neglected tropical disease that is endemic in over 80 countries worldwide. It is 
caused by Leishmania species, insect vector borne protozoan parasites, and affects an estimated  
12 million people a year with a further 350 million people living at risk of infection [1]. At the present 
time a vaccine to prevent leishmaniasis is not available and treatment currently relies entirely on a 
limited arsenal of chemotherapeutics. For example, treatment of cutaneous leishmaniasis (CL) largely 
relies on the pentavalent antimonials such as sodium stibogluconate (Pentostam) and meglumine 
antimoniate (Glucantime) [2,3]. Both Pentostam and Glucantime have been in clinical use for over 70 years 
despite their associated problems, which include severe side-effects such as cardiotoxicity [4] and the 
fact that they require parenteral administration [5]. In addition, the use of pentavalent antimonials in 
the treatment of leishmaniasis is under threat from the emergence of drug resistance [6]. To date 
resistance has not been widespread in the field but Leishmania spp. resistance to Pentostam and 
Glucantime can be easily induced in the laboratory [7]. Amphotericin B (Fungizone) [8] and diamidine 
Pentamidine [9] are employed as second-line drugs in the treatment of CL. Like the antimonials, they 
induce severe side-effects and parasite resistance, although not yet conclusively confirmed in the field, 
has been observed under laboratory conditions [10]. Given the aforementioned issues with both the 
current first- and second-line drugs used to treat CL there is clearly a need to develop new and 
effective therapies for this disease. 
In recent years natural product antimicrobial peptides (AMPs) have been investigated as a potential 
new source of novel antileishmanials [11,12], in part this has been catalysed by the fact that they have 
displayed promising activity against other cutaneous infectious diseases [13]. The activity of AMPs 
against Leishmania species that give rise to CL has recently been reported. However, despite having 
promising activity against insect-stage promastigotes, the amphibian-derived temporin family of AMPs 
has shown limited efficacy against mammalian-stage amastigotes [14]. The predominant surface 
component of promastigote Leishmania is lipophosphoglycan (LPG), a large glycoconjugate which 
together with cell surface associated proteophosphogycan (PPG) forms a dense glycocalyx protecting 
the parasite from the mammalian innate immune response on inoculation from the sand fly vector [15]. 
Subsequently, following infection of macrophage cells and differentiation into the pathogenic 
amastigote form, expression of cell surface LPG and PPG is massively down-regulated [15,16]. Whilst 
it has previously been predicted that this thick, negatively charged layer protects the promastigote 
parasite from cationic AMPs by capturing them and preventing interaction with the cell surface [17], 
the relative resistance of amastigotes to temporin AMPs suggests the opposite. Herein, we report an 
extended study of the antileishmanial properties of temporins and the examination of the protective or 
sensitizing effects of LPG and PPG in L. mexicana, a causative agent of CL. 
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2. Results and Discussion 
2.1. The Antileishmanial Properties of Temporin Antimicrobial Peptides 
Temporins A, B, 1Sa, F and L were synthesized and analyzed as described in the Experimental 
Section. The sequences, formulae and accurate mass data are summarized in Table 1. As previously 
reported [14] temporin A displayed significant activity against L. mexicana promastigotes with an 
ED50 of 8 µM. Whilst temporin B demonstrated low potency with an ED50 of 38 µM (Figure 1A;  
Table 2). However, in contrast to the previous study [14] temporin 1Sa demonstrated good activity 
against these insect stage forms, an ED50 of 4 µM (Figure 1). The reasons for this divergence are not 
clear, however the previously synthesized 1Sa [14] demonstrated similar activity on reanalysis to that 
shown in Figure 1, indicating that the assay is likely to be the source of this discrepancy. Notably, 
serum is observed to mask the efficacy of the temporin peptides [14]. Therefore, it is likely that the 
serum was inadequately removed before assay in the previous study, thereby leading to the 
underestimation of 1Sa efficacy. To expand this work further temporins F and L were synthesized and 
purified as described, and then screened against L. mexicana promastigotes. Both AMPs showed good 
activity, F with an ED50 of 14 µM and L with an ED50 of 5 µM (Figure 1A; Table 2). 
Table 1. Tabulated sequences for the peptides tested including accurate mass data. The 
doubly charged ion was used for accurate mass measurements, i.e., [M+2H]2+. All peptides 
are amidated at the C terminus. Lysine (K) and arginine (R) are positively charged  
side chains. 
 
Peptide Sequence 
Empirical 
Formula 
Mass Calculated 
[M+2H]2+ 
Accurate Mass Found 
[M+2H]2+ 
Temporin A FLPLIGRVLSGIL-NH2 C68H117N17O14 698.9561 698.9548 
Temporin B LLPIVGNLLKSLL-NH2 C67H122N16O15 696.4716 696.4735 
Temporin 1Sa FLSGIVGMLGKLF-NH2 C67H109N15O14S 690.9078 690.9075 
Temporin F FLPLIGKVLSGIL-NH2 C68H117N15O14 684.9531 684.9504 
Temporin L FVQWFSKFLGRIL-NH2 C83H122N20O15 820.9792 820.9792 
Table 2. ED50 for temporins against wild type and mutant L. mexicana promastigotes and 
amastigotes. Mean ED50 (and range) shown for the values from at least 3 independent 
experiments performed in triplicate. 
Peptide 
ED50 (µM) 
L. mexicana 
Promastiogte 
L. mexicana 
Amastigote 
L. mexicana 
∆lpg1 
L. mexicana 
∆lpg2 
Temporin A 8 (6–14)  ~100 11 (8–16)  26 (21–39)  
Temporin B 38 (24–64)  >100 39 (28–70)  41 (40–41)  
Temporin 1Sa 4 (3–13) 42 (35–44) 6 (3–18)  31 (28–35)  
Temporin F 14 (10–27) >100 17 (13–29)  23 (16–49)  
Temporin L 5 (5–6) 83 (46–93)  4 (3–6) 9 (8–12) 
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Figure 1. Activity of the temporin peptides against wild type promastigote and amastigote 
L. mexicana. Using the alamarBlue® assay system, L. mexicana promastigote (A) and 
amastigote (B) viability in the presence of various concentrations (2–100 µM) of the 
temporin peptides was determined with respect to a DMSO control. Amphotericin B  
(2–100 µM) was utilized as a positive control. Data points represent the mean of  
3 independent experiments performed in triplicate. Standard deviation indicated. Cell 
viability <50% indicated by red bars. 
However, as previously noted [14], temporin A demonstrated drastically reduced activity against 
the clinically relevant amastigote form of L. mexicana (ED50 of approximately 100 µM), whilst 
temporin B was inactive at the maximal concentration tested, 100 µM. Similarly, temporin F was 
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inactive at 100 µM, whilst 1Sa and L had very low levels of activity against amastigote compared to 
promastigote forms (ED50 42 and 83 µM respectively; Figure 1B; Table 2). 
Temporins A, B and 1Sa have all demonstrated significant activity against axenic amastigotes forms 
of other Leishmania species, A and B against L. pifanoi [18] and 1Sa against L. infantum [19].  
L. infantum is an Old World species and a member of the L. donovani complex, causing visceral 
disease in the Mediterranean basin, which has subsequently spread to Latin America where it is 
sometimes known as L. chagasi [20]. Like L. mexicana, L. pifanoi is a New World species, however it 
is part of the subgenus Viannia whereas L. mexicana is part of the subgenus Leishmania which actually 
makes it more closely related to L. infantum [21]. The considerable evolutionary distance between 
these different species and subgenra may account for the differing levels of temporin activity observed 
against amastigotes. The distance is reflected in diversity in the predominant surface glycoconjugates 
LPG, PPG and glycoinositolphospholipids (GIPLs), macromolecules which play significant roles in 
the parasite’s interface with its insect and mammalian hosts [22]. However, whilst L. pifanoi and  
L. infantum have not been extensively analyzed, the levels of LPG and PPG in amastigotes from both 
Old and New World species are low or zero [15,16] indicating that other factors confer temperin 
susceptibility. GIPLs are maintained in both lifecycle stages and although L. pifanoi and L. infantum 
remain relatively unstudied, significant inter-species variations in GIPL structure have been elucidated. 
L. Viannia panamenensis decorates the conserved galactose-mannose, glycophosphoinositol core with 
galactose motifs, whereas L. donovani GIPLs are highly mannosylated when compared to the simpler 
L. mexicana structures [22]. It is possible that these significant variations account for the differential 
activity of some temporin AMPs against axenic amastigotes reported in the literature. 
2.2. The Role of Phosphoglycans in the Susceptibility of L. Mexiciana to the Temporin Family of 
Antimicrobial Peptides 
Previously it has been postulated that LPG, which forms a thick negatively charged layer, protects 
the promatigote parasite from cationic AMPs by capturing them and preventing interaction with the 
cell surface [17]. However, the fact that amastigote L. mexicana possess little or no LPG at their 
surface [16], and yet are considerably more resistant to the temporin AMPs, argues against this 
hypothesis. Rather it suggests that LPG is a susceptibility factor, with the negatively charged 
macromolecule perhaps facilitating the concentration of these cationic peptides at the plasma 
membrane. To test this hypothesis the five temporins were assayed for their activity against L. mexicana 
promastigotes engineered to lack LPG, ∆lpg1 [23]. Targeted deletion of the β-galactofuranosyl 
transferase lpg1 in L. mexicana specifically blocked LPG expression, leaving the other 
phosphoglycans unaffected [23]. The results obtained were perhaps surprising, with the temporins 
showing little or no difference in efficacy against the ∆lpg1 mutant when compared with the wild type 
L. mexicana promastigotes (Figures 1A and 2A; Table 2). However, it is notable the that efficacy of 
temporins A and B have previously been reported to be unchanged against a similar, although less 
defined, L. donovani LPG mutant [18,24]. 
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Figure 2. Activity of the temporin peptides against ∆lpg1 and ∆lpg2 promastigote  
L. mexicana. Using the alamarBlue® assay system, L. mexicana ∆lpg1 (A) and ∆lpg2 (B) 
mutant promastigote viability in the presence of various concentrations (2–100 µM) of the 
temporin peptides was determined with respect to a DMSO control. Amphotericin B  
(2–100 µM) was utilized as a positive control. Data points represent the mean of  
3 independent experiments performed in triplicate. Standard deviation indicated. Cell 
viability <50% indicated by red bars. 
Proteophosphogylcans (PPGs) are a large range of secreted and cell surface associated parasite 
glycoconjugates which, like LPG, carry a negative charge [25]. Both axenic and intramacrophage  
L. mexicana amastigotes lack cell surface associated PPG, although the intracellular parasites do 
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secrete a form of PPG known as aPPG [26,27]. Targeted deletion of lpg2, a Golgi GDP-Man 
transporter, to create ∆lpg2 [25] prevented the formation of the phosphoglycan repeats that make up 
the backbone of LPG and PPG leaving the promastigote surface devoid of these negatively charged 
macromolecules. In contrast to the ∆lpg1 mutant, the ∆lpg2 promastigotes appeared less sensitive to all 
the temporins assayed, with the exception temporin B which was the least active of the AMPs against 
wild type promastigote forms. Temporins A, 1Sa and L showed the greatest difference in efficacy 
between wild type and ∆lpg2 promastigotes (temporin A: ED50 8 µM in wild type vs. ED50 26 µM in 
∆lpg2; 1Sa: 4 vs. 31; L: 5 vs. 9), with the activity of 1Sa against the mutant close to that of the 
generically resistant amastigote form (ED50 42 µM in amastigotes vs. ED50 31 µM in ∆lpg2). This 
indicated that PPG plays a role in promastigote sensitivity to the temporins (Figures 1 and 2B; Table 2) 
perhaps due to its negative charge attracting the cationic AMPs to the plasma membrane. However, it 
is notable that the clinical antileishmanial amphotericin B (used as a control in these experiments) is 
also less effective against ∆lpg2 L. mexicana (Figure 2B) indicating that the lack of PPG is leading to a 
generic increase in resistance to disruptors of the parasite cell surface. Like the temporins, 
amphotericin B is a pore forming compound [28]. 
3. Experimental Section 
3.1. Materials and Reagents 
Abbreviations for reagents are as follows: tert-butoxycarbonyl (Boc); 9-fluorenylmethoxylcarbonyl 
(Fmoc); trifluoroacetic acid (TFA); triisopropylsilyl (TIPS); N,N-dimethylformamide (DMF); dimethyl 
sulfoxide (DMSO). Solvents and reagents were purchased from commercial sources and used without 
further purification unless otherwise noted. Rink amide resin (typical loading level 0.6–0.8 mmol/g) 
was purchased from Merck4Biosciences (Darmstadt, Germany). DMF was purchased from AGTC 
Bioproducts (National Diagnostics, Hessle, UK). Piperidine and DIPEA were purchased from Sigma 
Aldrich (Gillingham, UK), PyBOP from Apollo Scientific (Stockport, UK) and Fmoc-protected amino 
acids from Novabiochem (Merck, Nottingham, UK). Preparative RP-HPLC was performed with a 
semi-preparative Perkin Elmer (Waltham, MA, USA) Series 200 lc pump fitted with a 785A UV/Vis 
detector using a SB-Analytical ODH-S optimal column (250 × 10 mm, 5 µm, Waters Ltd, Elstree, UK); 
flow rate 2 mL/min. Peptides were characterised by accurate LC-MS (QToF mass spectrometer and an 
Acquity UPLC from Waters Ltd using an Acquity UPLC BEH C8 1.7 µm (2.1 mm × 50 mm) column 
(Waters Ltd) with a flow rate of 0.6 mL/min and a linear gradient of 5%–95% of solvent B over  
3.8 min (A = 0.1% formic acid in H2O, B = 0.1% formic acid in MeCN). Peptide identities were also 
confirmed by MALDI-TOF mass spectra analysis (Autoflex II ToF/ToF mass spectrometer Bruker 
Daltonik GmBH, (Coventry, UK) operating in positive ion mode using an α-cyano-4-hydroxycinnamic 
acid (CHCA) matrix. Data processing was done with MestReNova Version 8.1. 
3.2. Peptide Synthesis 
Rink Amide AM resin (200–400 mesh, 0.79 mmol/g loading) and all Fmoc-protected amino acids 
used were purchased from Novabiochem, Merck. PyBOP™ was purchased from CEM (Buckingham, 
UK). HPLC grade solvents were obtained from Fisher Scientific (Loughborough, UK) and all other 
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reagents from Sigma Aldrich. Side chain protecting groups utilised for the Fmoc amino acids were  
t-butyl for Ser, Pbf for Arg, Boc for Lys and Trt for Asn. Temporins A, B and 1Sa were prepared as 
previously described [14]. Temporins A, B, 1Sa, F and L were prepared via manual Fmoc SPPS. 
Peptides were synthesised on a 0.1 mmol scale (127 mg of Rink Amide AM resin). Fmoc amino acids 
(2 equiv.) were coupled using PyBOP (2 equiv.) and DIPEA (4 equiv.) at RT for 1 h on a shaker  
(380 RPM, manual procedure). For the first C-terminus amino acid, double coupling was used. Also all 
amino acids from the 7th position were double coupled to increase the yield. Fmoc deprotection was 
carried out using piperidine/DMF (20% v/v) for 5 and then 10 min at RT. Final peptide cleavage was 
achieved using TFA:TIPS:H2O 95:5:5 (4 mL) at 25 °C with stirring for a minimum of 4 h. The 
cleavage cocktail was collected, the solvent removed in vaccuo, the crude peptides dissolved in 
acidified H2O (0.1% TFA) and lyophilised. Crude peptides were purified by semi-preparative  
RP-HPLC, by use of a Perkin Elmer series 200 LC pump, 785A UV/Vis detector, using a  
250 mm × 10.0 mm, 5 µm SB analytical column; flow rate = 2 mL/min linear gradient elution  
0%–100% B over 60 min (A = 0.1% TFA in 95% H2O and 5% CH3CN, B = 0.1% TFA in 5% H2O and 
95% CH3CN) at λ = 220 or 250 nm. Relevant fractions were collected, lyophilized, and analysed by  
LC–MS, MALDI-TOF MS and analytical HPLC. See Supplemental Materials for analytical data 
(MALDI-TOF MS spectra and analytical HPLC spectra). Temporin A [FLPLIGRVLSGIL-NH2], 
temporin B [LLPIV GNLLKSLL-NH2], temporin 1Sa [FLSGIVGMLGKLF-NH2], temporin F 
[FLPLIGKVLSGIL-NH2], and temporin L [FVQWFSKFLGRIL-NH2]. 
3.3. Antileishmanial Assay 
Leishmania mexicana (MNYC/BZ/62/M379) wild type and LPG mutant parasites (∆lpg1 [23] and 
∆lpg2 [25]) were maintained at 26 °C in Schneider’s Drosophila media (Sigma Aldrich) supplemented 
with heat inactivated foetal bovine sera (15% for promastigotes and mutants, and 20% for amastigotes; 
Biosera). Promastigotes were transformed into axenic amastigotes by a pH and temperature shift as 
previously described [29]. Cells were counted using a Neubauer Improved Haemocytometer. Cytotoxicity 
analyses were performed in 96-well plates (Costar, Corning Inc., Amsterdam, The Netherlands) using 
alamarBlue® (Life Technologies, Paisley, UK) with some modifications to the published, optimized 
protocol [14]. Briefly, to mitigate against the effects of serum on the efficacy of the peptides, 
promastigote and amastigote L. mexicana were preincubated (26 °C for promatastigotes; 33 °C for 
amastigotes) with the temporins (2–100 µM) in 10 µL of serum-free media at 4 × 106 mL−1 for 1 h 
before the addition of 90 µL of complete media. Following incubation at the appropriate temperature 
for 24 h, 10 µL of alamarBlue® was added to each well and the plates incubated for a further 4 h prior to 
assessing cell viability using a fluorescent plate reader (Biotek UK, Potton, UK; 560EX nm/600EM nm). 
All data points were in triplicate, with amphotericin B as positive and DMSO as negative controls. All 
of the experiments described above were carried out on a minimum of three separate occasions to 
ensure a robust data set was collected. 
4. Conclusions 
In summary, L. mexicana amastigotes are generically resistant to the temporin family of AMPs. 
This is not attributably to their lack of LPG when compared to the insect stage promastigote form. 
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However, promastigote L. mexicana lacking both LPG and the other major negatively charged surface 
macromolecule PPG are notably more resistant to the temporin AMPs than either wild type or the LPG 
mutant promastigotes. Given that amastigote L. mexicana lack LPG and surface-associated PPG, it 
may be considered that the cell surface of these mutant promastigotes resembles that of the mammalian 
pathogenic form [26,27], leading to the hypothesis that PPG is at least partly responsible for the 
sensitivity of promastigote compared to amastigote L. mexicana. Notably, for temporin 1Sa, the ED50 
against ∆lpg2 L. mexicana promastigotes (lacking both of LPG and PPG; 31 µM) was closer to that 
established for amastigote form (49 µM) than the wild type promastigote form (4 µM; Table 2;  
Figures 1 and 2). This indicated that, at least for temporin 1Sa, PPG is a major factor in promastigote 
sensitivity. As hypothesized, this could be due to the highly negatively charged PPG attracting the 
cationic temporin peptides towards their site of action, the plasma membrane. However, alternative 
explanations are conceivable. For example, both LPG and cell surface associated PPG are 
glycophosphoinositol lipid-anchored to the Leishmania plasma membrane [30] and their absence may 
significantly alter membrane fluidity and, perhaps, AMP sensitivity. Whatever the mechanism it is 
clear that the loss PPG (together with LPG) increases the resistance of L. mexicana to a range of 
temporin AMPs. Given the lack of these predominant macromolecules in pathogenic amastigote forms 
this may preclude their development as antileishmanials, however secreted PPG associates with  
L. major promastigotes to form a mucin-like coat [31]. Given that intramacrophage (but not axenic)  
L. mexicana amastigotes secrete a form of PPG, aPPG [26,27], it is possible that the presence of this 
macromolecule within the phagolysosome, and its potential association with the parasite cell surface, 
will sensitize the pathogen to the temporin AMPs. 
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Supplementary materials can be accessed at: http://www.mdpi.com/1420-3049/20/02/2775/s1. 
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